Therefore, in view of this and in the wake of what has been proposed for anti‐IL‐1 drugs in the opening of this discussion, next to the new alarmin‐based approaches, a promising and feasible investigation scenario for the future might involve the use, also in cutaneous malignant melanoma and, more extensively, other intractable skin disorders,108 of anti‐alarmin drugs already employed and proven effective for other diseases. This evidence concerns the gene IL1A and skin disorder.